Skip to navigation bar Skip to breadcrumbs Skip to page content
clear place holder
Envelope icon E-mail Updates Teal square Text size:  a A A

Clinical Summary

Ovarian Cancer: Screening

Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Clinical Summary of U.S. Preventive Services Task Force Reaffirmation Recommendation

Release Date: September 2012

Population Asymptomatic women without known genetic mutations that increase risk for ovarian cancer
Recommendation Do not screen for ovarian cancer.

Grade: D

Risk Assessment Women with BRCA1 and BRCA2 genetic mutations, the Lynch syndrome (hereditary nonpolyposis colon cancer), or a family history of ovarian cancer are at increased risk for ovarian cancer.

Women with an increased-risk family history should be considered for genetic counseling to further evaluate their potential risks. "Increased-risk family history" generally means having 2 or more first- or second-degree relatives with a history of ovarian cancer or a combination of breast and ovarian cancer; for women of Ashkenazi Jewish descent, it means having a first-degree relative (or 2 second-degree relatives on the same side of the family) with breast or ovarian cancer.

Screening Tests Transvaginal ultrasonography and serum cancer antigen (CA)–125 testing are the most commonly suggested screening modalities.
Treatments Treatment of ovarian carcinoma includes surgical treatment (debulking) and intraperitoneal or systemic chemotherapy.
Balance of Benefits and Harms Annual screening with transvaginal ultrasonography and serum CA-125 testing in women does not decrease ovarian cancer mortality.

Screening for ovarian cancer can lead to important harms, including major surgical interventions in women who do not have cancer.

Therefore, the harms of screening for ovarian cancer outweigh the benefits.

Relevant USPSTF Recommendations The USPSTF has made a recommendation on genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility. This recommendation is available at http://www.uspreventiveservicestaskforce.org/

For a summary of the evidence systematically reviewed in making these recommendations, the full recommendation statement, and supporting documents, please go to http://www.uspreventiveservicestaskforce.org.

Disclaimer: Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
 

Current as of: September 2012

Internet Citation: Clinical Summary: Ovarian Cancer: Screening. U.S. Preventive Services Task Force. October 2014.
https://www.uspreventiveservicestaskforce.org/Page/Document/ClinicalSummaryFinal/ovarian-cancer-screening

USPSTF Program Office   5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857